Turn Internal Assumptions Into Investor-Ready Insight
Independent verification of program logic, targets, and mechanisms for funding decisions or due diligence.
The Gap in Current Workflows
- Investors rely on internal data, models, and PI claims — often siloed and unverified.
- Standard analysis cannot quantify global novelty, mechanism robustness, or comparative program risk.
Why Independent Validation Matters
- Offers confidence for investors and boards with structured scoring and cross-program benchmarking.
- Reduces uncertainty around translational feasibility and competitive positioning.
The Reasoning Layer
Multi-institutional dataset aggregation identifies trends, gaps, and directional signals — without exposing any individual contributor's data.
- Multi-institutional dataset aggregation identifies trends, gaps, and directional signals.
- Data remains confidential; insights are presented in anonymised, strategic metrics.
How It Works
Commission your diligence report before a financing round, board presentation, or partnership discussion.
- Provide program context, targets, and hypotheses.
- Report delivers comparative validation, novelty benchmarking, and actionable scoring for investment decisions.
Related reports
Explore adjacent validation types within your decision workflow.
View all Biotech validation reports for the full cluster overview and internal navigation.
Strategic Audit
Request an investor diligence report
Independent program assessment for biotech investors and boards. Structured scientific validation for funding decisions.